Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (Note: Input metadata referenced "Bio Green Med Solution, Inc.", but the filing text identifies the registrant as Cyclacel Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2025
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) and unregistered sale of equity securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key metrics related to the transaction include:
- Gross Proceeds: $1,000,000
- Securities Issued: 1,000,000 shares of Series E Convertible Preferred Stock
- Purchase Price: $1.00 per share
- Conversion Ratio: 1 share of Series E Preferred Stock converts into 110 shares of Common Stock
- Use of Proceeds: General corporate and operating purposes
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. These metrics are not included in this specific 8-K report.
Material Changes
The primary material change is the issuance of new equity securities and the modification of rights for security holders:
- Capital Structure: Issuance of 1,000,000 shares of Series E Preferred Stock to accredited investors.
- Ownership Limitation: Conversion is capped so that no investor holds more than the lower of (i) the maximum percentage allowed under Nasdaq rules without a stockholder vote, or (ii) 4.99% of the Common Stock outstanding immediately before the original issue date.
- Voting Rights: Series E Preferred Stock votes together with Common Stock on an as-converted basis, subject to the ownership limitation.
- Liquidation Preference: Holders are entitled to $1.00 per share plus accrued dividends prior to any distribution to Common Stockholders.
Guidance, Outlook, and Risks
Management Commentary and Next Steps:
- The Company agreed to attempt to hold a special meeting of stockholders.
- Proposals for the meeting include: (i) issuance of all Common Stock to Investors in compliance with Nasdaq rules (removing conversion limitations), and (ii) an increase in authorized Common Stock to a minimum of 600,000,000 shares.
Risks and Contingencies:
- Stockholder Approval: There is a risk that the Company may not be successful in receiving the stockholder approval required to issue the shares of Common Stock pursuant to the contemplated transactions.
- Forward-Looking Statements: Actual results may differ materially from expectations due to risks described in the Company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the status of the special stockholder meeting to approve the issuance of Common Stock upon conversion.
- Confirm the current number of outstanding Common Stock shares to calculate the potential dilution impact of the 110:1 conversion ratio.
- Review the full text of the Series E Certificate of Designations (Exhibit 3.1) and Securities Purchase Agreement (Exhibit 10.1) for detailed terms.
- Check recent Form 10-K and 10-Q filings for the Company's current liquidity position and cash burn rate to assess the sufficiency of the $1 million raise.